{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:26:22Z","timestamp":1786436782229,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1007\/s00105-004-0802-8","type":"journal-article","created":{"date-parts":[[2004,10,25]],"date-time":"2004-10-25T08:12:31Z","timestamp":1098691951000},"page":"1130-1136","source":"Crossref","is-referenced-by-count":55,"title":["Antipruritische Therapie mit dem oralen Opiatrezeptorantagonisten Naltrexon","Antipruritic therapy with the oral opioid receptor antagonist naltrexone"],"prefix":"10.1007","volume":"55","author":[{"given":"A.","family":"Brune","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Metze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. A.","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"St\ufffdnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"CR1","first-page":"355","volume":"21","author":"Andersen","year":"1984","unstructured":"Andersen LW, Friedberg M, Lokkegaard N (1984) Naloxone in the treatment of uremic pruritus: a case history. Clin Nephrol 21:355?356","journal-title":"Clin Nephrol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/0091-6749(88)90571-4","volume":"81","author":"Banerji","year":"1988","unstructured":"Banerji D, Fox R, Seleznick M, Lockey R (1988) Controlled antipruritic trial of nalmefene in chronic urticaria and atopic dermatitis. J Allergy Clin Immunol 81:252 (Abstr.)","journal-title":"J Allergy Clin Immunol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-123-3-199508010-00001","volume":"123","author":"Bergasa","year":"1995","unstructured":"Bergasa NV, Alling DW, Talbot TL et al. (1995) Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 123:161?167","journal-title":"Ann Intern Med"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.510270307","volume":"27","author":"Bergasa","year":"1998","unstructured":"Bergasa NV, Schmitt JM, Talbot TL et al. (1998) Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 27:679?684","journal-title":"Hepatology"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0190-9622(99)70117-9","volume":"41","author":"Bergasa","year":"1999","unstructured":"Bergasa NV, Alling DW, Talbot TL et al. (1999) Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 41:431?434","journal-title":"J Am Acad Dermatol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/archderm.1979.04010110058029","volume":"115","author":"Bernstein","year":"1979","unstructured":"Bernstein JE, Swift R (1979) Relief of intractable pruritus with naloxone. Arch Dermatol 115:1366?1367","journal-title":"Arch Dermatol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/1523-1747.ep12497974","volume":"78","author":"Bernstein","year":"1982","unstructured":"Bernstein JE, Swift RM, Soltani K, Lorincz AL (1982) Antipruritic effect of an opiate antagonist, naloxone hydrochloride. J Invest Dermatol 78:82?83","journal-title":"J Invest Dermatol"},{"key":"CR8","unstructured":"Ghura HS, Patterson AD, Carmichael AJ (1998) Naltrexone in the treatment of renal itch. Br J Dermatol 139 [Suppl 51]:64"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00003495-198835030-00002","volume":"35","author":"Gonzalez","year":"1988","unstructured":"Gonzalez JP, Brogden RN (1988) Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35:192?213","journal-title":"Drugs"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0304-3959(97)00098-5","volume":"73","author":"Heyer","year":"1997","unstructured":"Heyer G, Dotzer M, Diepgen TL, Handwerker HO (1997) Opiate and H1 antagonist effects on histamine induced pruritus and alloknesis. Pain 73:239?243","journal-title":"Pain"},{"key":"CR11","first-page":"1207","volume":"29","author":"Lee","year":"1988","unstructured":"Lee MC, Wagner HN, Tanada S et al. (1988) Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 29:1207?1211","journal-title":"J Nucl Med"},{"key":"CR12","first-page":"533","volume":"41","author":"Metze","year":"1999","unstructured":"Metze D, Reimann S, Beissert S, Luger T (1999) Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 41:533?539","journal-title":"J Am Acad Dermatol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0190-9622(89)80353-6","volume":"21","author":"Monroe","year":"1989","unstructured":"Monroe EW (1989) Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 21:135?136","journal-title":"J Am Acad Dermatol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1681\/ASN.V113514","volume":"11","author":"Pauli-Magnus","year":"2000","unstructured":"Pauli-Magnus C, Mikus G, Alscher DM et al. (2000) Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 11:514?519","journal-title":"J Am Soc Nephrol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(96)04176-1","volume":"348","author":"Peer","year":"1996","unstructured":"Peer G, Kivity S, Agami O et al. (1996) Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 348:1552?1554","journal-title":"Lancet"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1523\/JNEUROSCI.17-20-08003.1997","volume":"17","author":"Schmelz","year":"1997","unstructured":"Schmelz M, Schmidt R, Bickel A et al. (1997) Specific C-receptors for itch in human skin. J Neurosci 17:8003?8008","journal-title":"J Neurosci"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.7326\/0003-4819-97-5-788_3","volume":"97","author":"Smitz","year":"1982","unstructured":"Smitz S, Legros JJ, LeMaire M (1982) Naloxone, itch, asthma, urticaria, and angioedema. Ann Intern Med 97:788?789","journal-title":"Ann Intern Med"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0167-0115(02)00159-3","volume":"110","author":"St\u00e4nder","year":"2002","unstructured":"St\u00e4nder S, Gunzer M, Metze D et al. (2002) Localization of ?-opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept 110:75?83","journal-title":"Regul Pept"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1610-0387.2003.02023.x","volume":"1","author":"St\u00e4nder","year":"2003","unstructured":"St\u00e4nder S, Weisshaar E, Steinhoff M et al. (2003) Pruritus?Pathophysiologie, Klinik und Therapie?Eine \u00dcbersicht. JDDG 1:105?118","journal-title":"JDDG"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1001\/archderm.139.11.1463","volume":"139","author":"St\u00e4nder","year":"2003","unstructured":"St\u00e4nder S, Steinhoff M, Schmelz M et al. (2003) Neurophysiology of pruritus. Cutaneous elicitation of itch. Arch Dermatol 139:1463?1470","journal-title":"Arch Dermatol"},{"key":"CR21","unstructured":"St\u00e4nder S, Metze D (2004) Treatment of pruritus in internal and dermatological diseases with opioid receptor antagonists. In: Yosipovitch G, Greaves MW, Fleischer AB, McGlone F (eds) Itch: basic mechanisms and therapy. Marcel Dekker, New York, pp 259?277"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199506223322506","volume":"332","author":"Stein","year":"1995","unstructured":"Stein C (1995) The control of pain in peripheral tissue by opioids. N Engl J Med 332:1685?1690","journal-title":"N Engl J Med"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2133.1981.tb00985.x","volume":"105","author":"Summerfield","year":"1981","unstructured":"Summerfield JA (1981) Pain, itch and endorphins. Br J Dermatol 105:725?726","journal-title":"Br J Dermatol"},{"key":"CR24","first-page":"809","volume":"240","author":"Tao","year":"1987","unstructured":"Tao PL, Law PY, Loh HH (1987) Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment. J Pharmacol Exp Ther 240:809?816","journal-title":"J Pharmacol Exp Ther"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","volume":"113","author":"Wolfhagen","year":"1997","unstructured":"Wolfhagen FH, Sternieri E, Hop WC et al. (1997) Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 113:1264?1269","journal-title":"Gastroenterology"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-004-0802-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-004-0802-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-004-0802-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T22:32:14Z","timestamp":1624746734000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-004-0802-8"}},"subtitle":["Offene, nicht placebokontrollierte Anwendung bei 133\ufffdPatienten","Open, non-placebo controlled administration in 133 patients"],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1007\/s00105-004-0802-8","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}